Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Rachel Rabinovitch

Concepts (352)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
61
2025
2249
4.040
 Why?
Mastectomy, Segmental
29
2025
93
2.200
 Why?
Hodgkin Disease
8
2022
139
1.550
 Why?
Lymphoma, Large B-Cell, Diffuse
8
2023
125
1.510
 Why?
Brachytherapy
10
2019
120
1.360
 Why?
Carcinoma, Intraductal, Noninfiltrating
8
2025
56
1.350
 Why?
Neoplasm Staging
34
2020
1377
1.120
 Why?
Neoplasm Recurrence, Local
14
2025
1060
1.120
 Why?
Mediastinal Neoplasms
3
2017
45
1.090
 Why?
Radiotherapy, Adjuvant
17
2025
218
1.000
 Why?
Radiotherapy, Conformal
7
2016
70
0.950
 Why?
Mastectomy
7
2025
139
0.890
 Why?
Radiation Pneumonitis
1
2024
29
0.880
 Why?
Combined Modality Therapy
25
2024
1241
0.870
 Why?
Lymphoma, Follicular
4
2023
40
0.800
 Why?
Radiation Oncologists
1
2021
5
0.740
 Why?
Antineoplastic Combined Chemotherapy Protocols
11
2021
1695
0.710
 Why?
Carcinoma, Ductal, Breast
10
2016
83
0.600
 Why?
Radiotherapy Planning, Computer-Assisted
6
2020
129
0.570
 Why?
Female
79
2025
73162
0.520
 Why?
Breast
3
2013
153
0.510
 Why?
Middle Aged
53
2025
33355
0.510
 Why?
Mammography
5
2019
151
0.510
 Why?
Cord Blood Stem Cell Transplantation
3
2024
99
0.490
 Why?
SEER Program
7
2019
218
0.490
 Why?
Humans
107
2025
137514
0.490
 Why?
Aged, 80 and over
20
2025
7593
0.490
 Why?
Lymphoma, B-Cell
1
2016
107
0.460
 Why?
Prognosis
16
2024
4031
0.460
 Why?
Radiotherapy Dosage
13
2025
267
0.450
 Why?
Aged
40
2025
23798
0.450
 Why?
Transplantation Conditioning
5
2024
170
0.440
 Why?
Lymph Nodes
5
2016
493
0.430
 Why?
Kaplan-Meier Estimate
6
2020
892
0.430
 Why?
Breast Neoplasms, Male
1
2013
28
0.430
 Why?
Proportional Hazards Models
6
2022
1263
0.420
 Why?
Treatment Outcome
21
2025
10821
0.420
 Why?
Neoplasms, Second Primary
3
2020
115
0.410
 Why?
BRCA2 Protein
3
2020
63
0.400
 Why?
Radiosurgery
2
2019
346
0.400
 Why?
Receptor, ErbB-2
5
2024
342
0.400
 Why?
Adult
45
2025
37821
0.390
 Why?
Radiotherapy
6
2015
201
0.380
 Why?
Lymphoma, Non-Hodgkin
3
2021
88
0.380
 Why?
Follow-Up Studies
11
2024
5139
0.380
 Why?
Healthcare Disparities
1
2018
651
0.380
 Why?
Prostatic Neoplasms
4
2022
1034
0.370
 Why?
Survival Analysis
9
2018
1320
0.360
 Why?
Mammaplasty
1
2013
113
0.360
 Why?
Delivery of Health Care
1
2018
948
0.360
 Why?
Lymphoma
2
2025
207
0.330
 Why?
Hematopoietic Stem Cell Transplantation
4
2024
614
0.330
 Why?
Whole-Body Irradiation
5
2020
78
0.330
 Why?
BRCA1 Protein
2
2020
76
0.330
 Why?
Disease-Free Survival
8
2025
690
0.320
 Why?
Anthracyclines
1
2009
49
0.310
 Why?
Medical Oncology
3
2021
290
0.310
 Why?
Radiation Oncology
5
2025
83
0.310
 Why?
Neoplasms, Radiation-Induced
3
2020
92
0.300
 Why?
Sentinel Lymph Node Biopsy
3
2008
116
0.300
 Why?
Antibiotics, Antineoplastic
1
2009
130
0.300
 Why?
Bile Duct Diseases
1
2008
14
0.290
 Why?
Graft vs Host Disease
5
2024
249
0.280
 Why?
Cholestasis, Intrahepatic
1
2008
39
0.280
 Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2017
73
0.280
 Why?
Neoplasm Grading
6
2022
308
0.280
 Why?
Bile Ducts, Intrahepatic
1
2008
78
0.280
 Why?
Radiotherapy, Intensity-Modulated
3
2014
143
0.280
 Why?
Thoracic Vertebrae
1
2007
78
0.270
 Why?
United States
16
2019
14696
0.270
 Why?
Prostheses and Implants
1
2007
141
0.250
 Why?
Trastuzumab
3
2024
101
0.250
 Why?
Nutritional Support
1
2006
34
0.250
 Why?
Heart Diseases
1
2009
359
0.240
 Why?
Orbital Neoplasms
1
2025
24
0.230
 Why?
Receptors, Estrogen
4
2016
435
0.230
 Why?
Young Adult
9
2025
13243
0.230
 Why?
Survival Rate
8
2019
1980
0.230
 Why?
Transplantation, Haploidentical
1
2024
22
0.220
 Why?
Male
28
2025
67718
0.220
 Why?
Lymphoma, Mantle-Cell
1
2023
20
0.210
 Why?
Time Factors
5
2018
6817
0.200
 Why?
Flutamide
2
2018
5
0.190
 Why?
Goserelin
2
2018
7
0.190
 Why?
Neoadjuvant Therapy
3
2025
405
0.190
 Why?
Adolescent
11
2025
21555
0.180
 Why?
Analysis of Variance
2
2015
1324
0.180
 Why?
Patient Care Planning
2
2021
155
0.180
 Why?
Head and Neck Neoplasms
2
2010
617
0.180
 Why?
Neoplasm Invasiveness
4
2019
510
0.180
 Why?
Cause of Death
2
2016
431
0.180
 Why?
Survivorship
1
2021
49
0.180
 Why?
Bone Neoplasms
2
2018
250
0.180
 Why?
Deoxycytidine
1
2022
176
0.170
 Why?
Androgen Antagonists
2
2022
82
0.170
 Why?
Tumor Burden
4
2016
311
0.170
 Why?
Adenocarcinoma
2
2018
937
0.170
 Why?
Carcinoma, Squamous Cell
1
2006
683
0.170
 Why?
Azacitidine
1
2021
141
0.170
 Why?
Retrospective Studies
12
2025
15628
0.170
 Why?
Immunoconjugates
1
2021
116
0.170
 Why?
Clinical Trials as Topic
5
2017
1047
0.160
 Why?
Antineoplastic Agents, Immunological
2
2019
191
0.160
 Why?
Antibodies, Monoclonal, Humanized
2
2017
807
0.160
 Why?
Surgical Instruments
1
2000
52
0.160
 Why?
Antineoplastic Agents
7
2017
2145
0.160
 Why?
Radiation Injuries
3
2016
147
0.160
 Why?
Biomarkers, Tumor
2
2024
1279
0.160
 Why?
Patient Satisfaction
2
2013
657
0.150
 Why?
Neoplasms
2
2011
2666
0.150
 Why?
Vidarabine
3
2018
33
0.150
 Why?
Leuprolide
1
2018
19
0.150
 Why?
Practice Guidelines as Topic
5
2017
1580
0.150
 Why?
Public Health Surveillance
1
2018
80
0.150
 Why?
Thiotepa
1
2018
20
0.150
 Why?
Aquaporin 4
1
2019
96
0.150
 Why?
Necrosis
1
2019
244
0.140
 Why?
Randomized Controlled Trials as Topic
8
2022
1465
0.140
 Why?
Diphosphonates
1
2018
66
0.140
 Why?
Rituximab
2
2016
178
0.140
 Why?
Leukemia, Myeloid, Acute
2
2021
620
0.140
 Why?
Aromatase Inhibitors
1
2017
53
0.140
 Why?
Imidazoles
1
2018
244
0.130
 Why?
Patient Care Management
1
2017
56
0.130
 Why?
Chemoradiotherapy
1
2018
226
0.130
 Why?
Disease Management
2
2018
625
0.130
 Why?
Lymphoma, Extranodal NK-T-Cell
1
2016
9
0.130
 Why?
Unilateral Breast Neoplasms
1
2016
3
0.130
 Why?
Lymphoma, T-Cell, Peripheral
1
2016
16
0.130
 Why?
Multivariate Analysis
3
2009
1524
0.130
 Why?
Margins of Excision
1
2016
50
0.130
 Why?
Recurrence
5
2018
1060
0.130
 Why?
Chemotherapy, Adjuvant
6
2017
392
0.120
 Why?
Esthetics
2
2013
52
0.120
 Why?
Datasets as Topic
1
2016
120
0.120
 Why?
Programmed Cell Death 1 Receptor
1
2017
252
0.120
 Why?
Biopsy
5
2022
1132
0.120
 Why?
Risk Reduction Behavior
1
2016
220
0.120
 Why?
Quality of Life
2
2025
2870
0.120
 Why?
Risk Factors
5
2022
10356
0.110
 Why?
Prostate-Specific Antigen
3
2022
161
0.110
 Why?
Patient Selection
4
2016
691
0.110
 Why?
Cancer Survivors
1
2019
280
0.110
 Why?
Gastrointestinal Neoplasms
2
2012
79
0.110
 Why?
Propensity Score
1
2016
288
0.110
 Why?
Insurance Coverage
1
2016
228
0.110
 Why?
Gene Expression Profiling
3
2017
1770
0.110
 Why?
Carcinoma
1
2016
237
0.110
 Why?
Societies, Medical
4
2016
820
0.110
 Why?
Genetic Predisposition to Disease
2
2020
2420
0.110
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2014
88
0.110
 Why?
Immunotherapy, Adoptive
3
2023
324
0.110
 Why?
Practice Patterns, Physicians'
3
2017
1312
0.110
 Why?
Beauty
1
2013
19
0.110
 Why?
Receptors, Progesterone
2
2013
349
0.110
 Why?
Palliative Care
2
2018
738
0.110
 Why?
Lymphatic Irradiation
2
2010
10
0.100
 Why?
Triple Negative Breast Neoplasms
1
2016
202
0.100
 Why?
Diagnostic Self Evaluation
1
2013
23
0.100
 Why?
Axilla
3
2007
47
0.100
 Why?
Confidence Intervals
1
2013
328
0.100
 Why?
Prospective Studies
8
2022
7598
0.100
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1402
0.100
 Why?
Age Distribution
1
2013
391
0.100
 Why?
Sex Distribution
1
2013
378
0.100
 Why?
Lymphatic Metastasis
4
2019
351
0.100
 Why?
Carcinoma, Renal Cell
1
1994
214
0.090
 Why?
Immunotherapy
1
2016
647
0.090
 Why?
Cyclophosphamide
2
2009
251
0.090
 Why?
Guideline Adherence
2
2017
549
0.090
 Why?
Health Physics
1
2010
7
0.090
 Why?
Immunosuppressive Agents
3
2006
891
0.080
 Why?
Lung Neoplasms
2
2018
2494
0.080
 Why?
Four-Dimensional Computed Tomography
1
2010
30
0.080
 Why?
Antibodies, Monoclonal
1
2017
1428
0.080
 Why?
Boronic Acids
1
2010
38
0.080
 Why?
Doxorubicin
2
2009
368
0.080
 Why?
Clinical Trials, Phase III as Topic
2
2010
105
0.080
 Why?
Kidney Neoplasms
1
1994
400
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
51
0.080
 Why?
Pyrazines
1
2010
92
0.080
 Why?
Thrombophilia
1
2009
85
0.080
 Why?
Databases as Topic
1
2008
66
0.070
 Why?
Mutation
1
2020
3964
0.070
 Why?
Iridium Radioisotopes
1
2007
4
0.070
 Why?
Movement
1
2010
273
0.070
 Why?
Antineoplastic Agents, Hormonal
2
2008
161
0.070
 Why?
Registries
1
2016
2021
0.070
 Why?
Diagnostic Imaging
1
2010
339
0.070
 Why?
Positron-Emission Tomography
3
2017
299
0.070
 Why?
Sex Factors
1
2013
2074
0.070
 Why?
Prednisone
1
2008
245
0.070
 Why?
Comorbidity
3
2017
1618
0.070
 Why?
Fatigue
2
2025
329
0.070
 Why?
Syndrome
1
2008
359
0.070
 Why?
Incidence
1
2013
2792
0.070
 Why?
Sternum
1
2006
25
0.060
 Why?
Stomatitis
1
2006
14
0.060
 Why?
Age Factors
2
2017
3301
0.060
 Why?
Carcinoma, Small Cell
1
2006
172
0.060
 Why?
Risk Assessment
2
2025
3439
0.060
 Why?
Radiology
1
2008
181
0.060
 Why?
Conjunctival Neoplasms
1
2025
8
0.060
 Why?
Carcinoma, Ductal
1
2005
11
0.060
 Why?
Mycophenolic Acid
1
2006
117
0.060
 Why?
Lymphoma, B-Cell, Marginal Zone
1
2025
13
0.060
 Why?
Nomograms
1
2025
54
0.060
 Why?
Child
3
2024
22037
0.060
 Why?
Stem Cell Transplantation
1
2006
177
0.060
 Why?
Tacrolimus
1
2006
199
0.060
 Why?
Mastectomy, Modified Radical
2
2000
6
0.050
 Why?
Anemia, Sideroblastic
1
2003
3
0.050
 Why?
Living Donors
1
2006
295
0.050
 Why?
Radiography
2
2010
834
0.050
 Why?
Reproducibility of Results
5
2012
3292
0.050
 Why?
Tomography, X-Ray Computed
3
2009
2681
0.050
 Why?
Drug Resistance, Neoplasm
2
2019
806
0.050
 Why?
Drug Administration Schedule
2
2018
784
0.050
 Why?
Magnetic Resonance Imaging
3
2019
3722
0.050
 Why?
Mass Screening
1
2010
1264
0.050
 Why?
Referral and Consultation
1
2007
780
0.050
 Why?
Lymph Node Excision
3
2009
174
0.050
 Why?
Professional Staff Committees
1
2001
13
0.040
 Why?
Allografts
1
2021
148
0.040
 Why?
Antigens, CD19
1
2021
123
0.040
 Why?
Organ Size
2
2013
479
0.040
 Why?
Weight Loss
1
2006
770
0.040
 Why?
Automation
1
2020
95
0.040
 Why?
Carcinoma, Lobular
1
2000
49
0.040
 Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2021
228
0.040
 Why?
Germ-Line Mutation
1
2020
172
0.040
 Why?
Quality Assurance, Health Care
2
2012
324
0.040
 Why?
Risk Management
1
2020
91
0.040
 Why?
Respiration
2
2010
198
0.040
 Why?
Salvage Therapy
1
2000
143
0.040
 Why?
Workflow
1
2020
165
0.040
 Why?
Kallikreins
1
2018
29
0.040
 Why?
Myeloablative Agonists
1
2018
22
0.040
 Why?
Fetal Blood
1
2020
327
0.040
 Why?
Maximum Tolerated Dose
2
2010
199
0.040
 Why?
Sulfonamides
1
2021
513
0.030
 Why?
Radiopharmaceuticals
1
2018
178
0.030
 Why?
Osteoblasts
1
2018
126
0.030
 Why?
Neutropenia
2
2010
146
0.030
 Why?
Genomics
1
2022
793
0.030
 Why?
Aftercare
1
2019
210
0.030
 Why?
Canada
1
2018
421
0.030
 Why?
Retreatment
1
2017
72
0.030
 Why?
Asparaginase
1
2016
30
0.030
 Why?
Fat Necrosis
1
2016
9
0.030
 Why?
Metaplasia
1
2016
60
0.030
 Why?
Safety
1
2018
342
0.030
 Why?
Socioeconomic Factors
2
2017
1286
0.030
 Why?
Ultrasonography
1
2000
750
0.030
 Why?
Survivors
1
2019
489
0.030
 Why?
North America
1
2016
313
0.030
 Why?
Herpesvirus 4, Human
1
2016
167
0.030
 Why?
Europe
1
2016
414
0.030
 Why?
Heart
2
2010
660
0.030
 Why?
Genetic Variation
1
2020
986
0.030
 Why?
Postmenopause
2
2009
361
0.030
 Why?
T-Lymphocytes
1
2023
1999
0.030
 Why?
Gene Rearrangement
1
2016
151
0.030
 Why?
Proto-Oncogene Proteins c-myc
1
2016
141
0.030
 Why?
Catheterization, Peripheral
1
2016
111
0.030
 Why?
Proto-Oncogene Proteins c-bcl-2
1
2016
234
0.030
 Why?
Advisory Committees
1
2016
220
0.030
 Why?
DNA, Viral
1
2016
362
0.030
 Why?
Immunophenotyping
1
2016
321
0.030
 Why?
Radioimmunotherapy
1
2014
17
0.030
 Why?
Odds Ratio
1
2017
1063
0.030
 Why?
Actuarial Analysis
1
1994
27
0.030
 Why?
Clinical Decision-Making
1
2017
321
0.030
 Why?
Molecular Targeted Therapy
1
2017
414
0.030
 Why?
Child, Preschool
1
2008
11097
0.020
 Why?
Treatment Failure
1
1994
353
0.020
 Why?
Mass Media
1
2012
42
0.020
 Why?
Surveys and Questionnaires
1
2025
5772
0.020
 Why?
Anti-Bacterial Agents
1
2001
1800
0.020
 Why?
Ultrasonography, Mammary
1
2010
13
0.020
 Why?
Palpation
1
2010
15
0.020
 Why?
Logistic Models
1
2016
2064
0.020
 Why?
Urologic Neoplasms
1
2010
31
0.020
 Why?
Thoracic Neoplasms
1
2010
37
0.020
 Why?
Bortezomib
1
2010
54
0.020
 Why?
Lymphopenia
1
2010
61
0.020
 Why?
Subcutaneous Fat
1
2010
80
0.020
 Why?
Brain Neoplasms
1
2019
1241
0.020
 Why?
Nausea
1
2010
115
0.020
 Why?
Soft Tissue Neoplasms
1
2010
116
0.020
 Why?
Genital Neoplasms, Female
1
2010
88
0.020
 Why?
Pregnancy Trimester, Second
1
2009
79
0.020
 Why?
Radiation Dosage
1
2010
174
0.020
 Why?
Statistics, Nonparametric
1
2010
434
0.020
 Why?
Prevalence
1
2016
2719
0.020
 Why?
Infusions, Intravenous
1
2010
411
0.020
 Why?
Diarrhea
1
2010
183
0.020
 Why?
Pregnancy Trimester, First
1
2009
142
0.020
 Why?
Calcinosis
1
2010
235
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
188
0.020
 Why?
Premenopause
1
2009
125
0.020
 Why?
Longitudinal Studies
1
2016
2857
0.020
 Why?
Observer Variation
1
2009
347
0.020
 Why?
Perimenopause
1
2008
62
0.020
 Why?
Credentialing
1
2007
17
0.020
 Why?
Quality Control
1
2008
171
0.020
 Why?
In Situ Hybridization, Fluorescence
1
2008
319
0.020
 Why?
Fibrosis
1
2010
552
0.020
 Why?
Algorithms
1
2015
1702
0.020
 Why?
Medicare
1
2012
747
0.020
 Why?
Lung
2
2010
4066
0.020
 Why?
Evidence-Based Medicine
1
2010
746
0.020
 Why?
Benchmarking
1
2007
184
0.020
 Why?
Diagnosis, Differential
1
2010
1486
0.020
 Why?
Taxoids
1
2006
104
0.020
 Why?
Etoposide
1
2006
157
0.020
 Why?
Carboplatin
1
2006
144
0.020
 Why?
Signal Transduction
1
2019
5096
0.020
 Why?
Colorado
2
2010
4521
0.010
 Why?
Genital Diseases, Male
1
1985
17
0.010
 Why?
Dose-Response Relationship, Drug
1
2010
2066
0.010
 Why?
Genital Diseases, Female
1
1985
27
0.010
 Why?
Chlamydia trachomatis
1
1985
48
0.010
 Why?
Biomarkers
1
2016
4172
0.010
 Why?
Pharynx
1
1985
58
0.010
 Why?
Siblings
1
2006
228
0.010
 Why?
Neoplasm Proteins
1
2007
433
0.010
 Why?
Cisplatin
1
2006
318
0.010
 Why?
Immunohistochemistry
1
2008
1740
0.010
 Why?
Rectum
1
1985
185
0.010
 Why?
Hematologic Neoplasms
1
2006
158
0.010
 Why?
Feasibility Studies
1
2007
950
0.010
 Why?
Antilymphocyte Serum
1
2003
64
0.010
 Why?
Sexually Transmitted Diseases
1
1985
158
0.010
 Why?
Fatal Outcome
1
2003
305
0.010
 Why?
Transplantation, Homologous
1
2003
416
0.010
 Why?
Graft Rejection
1
2006
623
0.010
 Why?
Transplantation, Heterologous
1
2001
195
0.010
 Why?
Skin Neoplasms
1
2009
853
0.010
 Why?
Organizational Objectives
1
2001
73
0.010
 Why?
Hospitals, Private
1
1999
12
0.010
 Why?
Hospitals, County
1
1999
11
0.010
 Why?
Hospitals, University
1
1999
181
0.010
 Why?
Forecasting
1
2001
386
0.010
 Why?
Infant, Newborn
1
2009
6059
0.010
 Why?
Reoperation
1
2000
569
0.010
 Why?
Pregnancy
1
2009
6745
0.010
 Why?
Patient Education as Topic
1
1999
766
0.010
 Why?
Bacteriological Techniques
1
1985
71
0.000
 Why?
Chlamydia Infections
1
1985
74
0.000
 Why?
Risk
1
1985
905
0.000
 Why?
Sexual Behavior
1
1985
487
0.000
 Why?
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (352) concept(s)
_
Co-Authors Expand Description
See all (42) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)